AR108223A1 - Derivados de 6-oxo-1,6-dihidro-piridin-3-il - Google Patents
Derivados de 6-oxo-1,6-dihidro-piridin-3-ilInfo
- Publication number
- AR108223A1 AR108223A1 ARP170100985A ARP170100985A AR108223A1 AR 108223 A1 AR108223 A1 AR 108223A1 AR P170100985 A ARP170100985 A AR P170100985A AR P170100985 A ARP170100985 A AR P170100985A AR 108223 A1 AR108223 A1 AR 108223A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- cycloalkylalkyl
- heterocyclylalkyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 125000006416 CBr Chemical group BrC* 0.000 abstract 1
- 125000006414 CCl Chemical group ClC* 0.000 abstract 1
- 125000006415 CF Chemical group FC* 0.000 abstract 1
- 125000006417 CH Chemical group [H]C* 0.000 abstract 1
- 102000006947 Histones Human genes 0.000 abstract 1
- 108010033040 Histones Proteins 0.000 abstract 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical group CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 abstract 1
- -1 N- [2- (2,4-difluorophenoxy) -6- (1,5-dimethyl-6-oxopyridin-3-yl) pyrimidin-4-yl ] ethanesulfinamide Chemical compound 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 230000006718 epigenetic regulation Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324279P | 2016-04-18 | 2016-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108223A1 true AR108223A1 (es) | 2018-08-01 |
Family
ID=60039979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100985A AR108223A1 (es) | 2016-04-18 | 2017-04-18 | Derivados de 6-oxo-1,6-dihidro-piridin-3-il |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10202360B2 (enExample) |
| EP (1) | EP3445750A4 (enExample) |
| JP (2) | JP2019513804A (enExample) |
| AR (1) | AR108223A1 (enExample) |
| AU (1) | AU2017252276A1 (enExample) |
| TW (1) | TW201739744A (enExample) |
| WO (1) | WO2017184462A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI788343B (zh) | 2017-04-18 | 2023-01-01 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| CN110016014B (zh) * | 2018-01-08 | 2023-02-17 | 中国科学院上海药物研究所 | Ezh2抑制剂及其制备和抗肿瘤治疗中的应用 |
| CA3095367A1 (en) | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| CA3145827A1 (en) | 2019-07-02 | 2021-01-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| US20230174545A1 (en) * | 2020-04-29 | 2023-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| CN112225738B (zh) * | 2020-12-18 | 2021-04-13 | 北京鑫开元医药科技有限公司 | 作为tlr8激动剂的化合物、其制备方法、组合物及其用途 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
| CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
| AU2022380979A1 (en) | 2021-11-02 | 2024-06-06 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| EP4493558A1 (en) | 2022-03-17 | 2025-01-22 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
| US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
| BE786028A (fr) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2356005A1 (de) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung |
| AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
| US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
| CA2495338A1 (en) | 2002-09-26 | 2004-04-08 | Pfizer Inc. | Pyrazole amides for treating hiv infections |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US7723352B2 (en) | 2003-09-23 | 2010-05-25 | Merck Sharp & Dohme | Isoquinolinone potassium channel inhibitors |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| JP4978192B2 (ja) | 2004-04-01 | 2012-07-18 | アステラス製薬株式会社 | ピラジン誘導体およびその医薬的使用 |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| CN101228132B (zh) | 2005-07-26 | 2012-10-10 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物 |
| CN101228149B (zh) | 2005-07-26 | 2013-01-02 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的哌啶基取代的异喹啉酮衍生物 |
| US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| RU2457203C2 (ru) | 2006-12-27 | 2012-07-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолона |
| NZ577981A (en) | 2006-12-27 | 2011-12-22 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| AU2007338412B2 (en) | 2006-12-27 | 2013-03-14 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| CA2712897A1 (en) | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| CN102076686B (zh) | 2008-06-25 | 2013-03-06 | 百时美施贵宝公司 | 作为hiv附着抑制剂的二酮哌啶衍生物 |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| DK3070077T3 (en) | 2009-10-06 | 2019-04-01 | Millennium Pharm Inc | HETEROCYCLIC COMPOUNDS USING PDK1 INHIBITORS |
| CN102958930B (zh) | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| WO2012020786A1 (ja) * | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | 医薬組成物 |
| US9481670B2 (en) * | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CA2855019A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| CN103183675A (zh) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| JP6176244B2 (ja) * | 2012-05-30 | 2017-08-09 | 日本新薬株式会社 | 芳香族複素環誘導体及び医薬 |
| MX2015007921A (es) * | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
| HK1218909A1 (zh) * | 2013-03-12 | 2017-03-17 | Abbvie Inc. | 二氢-吡咯并吡啶酮布罗莫结构域抑制剂 |
| WO2014140077A1 (en) * | 2013-03-14 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
| CA2907912A1 (en) * | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| EA035727B1 (ru) * | 2013-10-18 | 2020-07-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы бромодомена |
| LT3092227T (lt) * | 2014-01-09 | 2018-08-10 | Orion Corporation | Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai |
| AU2015268962A1 (en) * | 2014-06-04 | 2017-01-12 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions |
| WO2018014802A1 (en) * | 2016-07-18 | 2018-01-25 | National Institute Of Biological Sciences, Beijing | Apoptosis inhibitors |
-
2017
- 2017-04-14 EP EP17786389.1A patent/EP3445750A4/en not_active Withdrawn
- 2017-04-14 JP JP2018554572A patent/JP2019513804A/ja active Pending
- 2017-04-14 WO PCT/US2017/027815 patent/WO2017184462A1/en not_active Ceased
- 2017-04-14 AU AU2017252276A patent/AU2017252276A1/en not_active Abandoned
- 2017-04-17 US US15/488,674 patent/US10202360B2/en active Active
- 2017-04-18 AR ARP170100985A patent/AR108223A1/es unknown
- 2017-04-18 TW TW106112891A patent/TW201739744A/zh unknown
-
2022
- 2022-01-31 JP JP2022013404A patent/JP2022064967A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170298040A1 (en) | 2017-10-19 |
| EP3445750A1 (en) | 2019-02-27 |
| WO2017184462A1 (en) | 2017-10-26 |
| JP2019513804A (ja) | 2019-05-30 |
| EP3445750A4 (en) | 2019-11-27 |
| US10202360B2 (en) | 2019-02-12 |
| JP2022064967A (ja) | 2022-04-26 |
| TW201739744A (zh) | 2017-11-16 |
| AU2017252276A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108223A1 (es) | Derivados de 6-oxo-1,6-dihidro-piridin-3-il | |
| PH12021500014A1 (en) | Fused ring compounds | |
| PH12021551065A1 (en) | Fused ring compounds | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| EA201990001A1 (ru) | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| MX374346B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| AR106099A1 (es) | Compuestos bicíclicos como inhibidores duales de atx / ca | |
| EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| BR112017017032A2 (pt) | derivados de mono e poliazanaftaleno substituídos e uso dos mesmos | |
| MX383124B (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus. | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MX387443B (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| EA201790206A1 (ru) | Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4 | |
| MX2018014164A (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico. | |
| CY1122497T1 (el) | Παραγωγα της 2-αμινοπυριδινης ως ανταγωνιστες του υποδοχεα αδενοσινης α2β και των συνδετων των υποδοχεων μτ3 μελατονινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |